An observational study in Reproductive Issues, Male Infertility and Asthenozoospermia, sponsored by Fecundis Lab SL. Recruiting at 4 sites in Spain. Open to male participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-01.
Sponsored by Fecundis Lab SL · Observational
Prospective, multicenter research study with a split-sample design on semen samples, without intervention, to evaluate the efficacy and safety of HyperSperm, a new sperm capacitation method, in 300 semen samples with various characteristics and abnormalities, in an in vitro study over 12 months.
282 studies on the registry are indexed under Infertility, Male; 65 are open to participants now.
This study's planned enrollment of 300 is above the median of 182 across 87 observational studies indexed under Infertility, Male.
Browse Infertility, Male studies →Fecundis Lab SL is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Men attending fertility clinics who provide a semen sample with normal parameters (normozoospermia), or present a male factor (asthenozoospermia, oligozoospermia, teratozoospermia, or a combination thereof).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Semen samples with normal sperm parameters as defined by the World Health Organization guidelines (e.g., normal sperm concentration, motility, and morphology).
Device: Standard sperm preparation · Device: HyperSperm
Semen samples with abnormal sperm morphology, where the percentage of morphologically normal sperm is below the threshold set by the World Health Organization (i.e., 4%).
Device: Standard sperm preparation · Device: HyperSperm
Semen samples characterized by reduced sperm motility, where the percentage of progressive motile sperm is below the threshold set by the World Health Organization (i.e., 32%).
Device: Standard sperm preparation · Device: HyperSperm
Semen samples with a low sperm concentration, below the World Health Organization reference value (i.e., less than 15 million sperm per milliliter).
Device: Standard sperm preparation · Device: HyperSperm
Semen samples that have been preserved through freezing and stored at ultra-low temperatures.
Device: Standard sperm preparation · Device: HyperSperm
Sperm samples in the control group will undergo traditional processing
Sperm samples in the experimental group will undergo product-specific processing
Hyperactivation
Percentage of sperm cells displaying hyperactivated motility
Time frame: 2 hours
Sperm vitality
Percentage of viable sperm cells
Time frame: 2 hours
DNA fragmentation
Percentage of TUNEL-positive sperm cells
Time frame: 2 hours
Sperm motility
Percentage of motile sperm cells
Time frame: 2 hours
Survival
Percentage of motile sperm cells after overnight incubation
Time frame: 20 hours
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.